Immunic (IMUX) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

IMUX Immunic

Watchlist

1.040
+0.010+0.97%

Trading Dec 19 10:16 ET

93.68MMarket Cap-0.85P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Immunic CEO Dr Daniel Vitt on Successful 2024, With More to Come in the Year Ahead | NASDAQ:IMUX
Proactive InvestorsDec 13 08:00 ET
Immunic CSO Discusses Breaking the IBD Stigma to Mark Crohn's and Colitis Awareness Week | NASDAQ:IMUX
Proactive InvestorsDec 2 04:15 ET
B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsNov 26 01:32 ET · Ratings
Immunic's Promising Pipeline Progress and Stable Financials Justify Buy Rating
TipRanksNov 26 01:05 ET · Ratings
Immunic, Inc. to Participate in Investor Conference in December
ImmunicNov 26 00:00 ET
Immunic Price Target Announced at $10.00/Share by HC Wainwright & Co.
Dow JonesNov 25 08:35 ET · Ratings

Comments

71261076

Yesterday 06:49

$Immunic (IMUX.US)$ The issue is they really have no product with final data while competitors move in with therapies that are FDA approved. The market for MS has many approved therapies. With each therapy approved, there is no immediate need for another one. Typically, this extends the approval time period. Even if data is very positive May of 2025 it will take 6 to 12 months for FDA to approve. So you will not see any real significant moves on this until 2026. By that time, they will need more...